Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arno Enrolls First Patient In Phase II Study Of AR-67
Arno Therapeutics (Arno) has reported the dosing of the first patient in a Phase II clinical study of its third-generation camptothecin compound, AR-67, in patients with glioblastoma multiforme
Arno Therapeutics (Arno) has reported the dosing of the first patient in a Phase II clinical study of its third-generation camptothecin compound, AR-67, in patients with glioblastoma multiforme
Synta Pharmaceuticals (Synta) has initiated a Phase 2 clinical study of STA-9090 in non-small cell lung cancer (NSCLC). STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor with a
The FDA has cleared Agendia’s MammaPrint breast cancer recurrence test for all ages. MammaPrint is the FDA-cleared breast cancer recurrence test available to patients and physicians. Over the
BASF has received the Environmental Protection Agency (EPA) approval for the use of Aseptrol S10 – tab in H1N1 sanitisation operations in institutional and industrial facilities, such as,
Takeda Pharmaceutical (Takeda) and Pfizer have entered into an agreement under which Pfizer in China will co-promote Takeda’s Actos (pioglitazone HCl) with Tianjin Takeda Pharmaceuticals in the country.
Unilife Medical Solutions (Unilife) has signed agreements for the construction of its new global headquarters and commercial production facility in York, Pennsylvania. The medical device production facility will
Cellular Dynamics International (CDI) has launched iCell Cardiomyocytes for use in testing of new drug candidates by the pharmaceutical industry. These human heart cells are designed to aid
As part of its effort to enter the fast-growing and high-potential Scar Management segment, Glenmark has in-licensed its first product for the Indian market. The company entered into
Ipca Laboratories has received approval for its anti-malarial finished fixed dose combination formulation of ‘Artemether + Lumefantrine’, under WHO’s Pre-qualification Programme. The product is now listed in the
Sanofi Pasteur has entered into an exclusive, world-wide licensing agreement with Syntiron to develop and commercialize its Prophylactic vaccine against staphylococcus, including methicillin-resistant staphylococcus aureus or MRSA. Under